OncoCyte Corp (OCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OncoCyte Corp (OCX) has a cash flow conversion efficiency ratio of -0.573x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($10.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OCX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
OncoCyte Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how OncoCyte Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OncoCyte Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OncoCyte Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyongbo Pharmaceutical Co Ltd
KO:214390
|
0.031x |
|
Solesence, Inc. Common Stock
NASDAQ:SLSN
|
0.061x |
|
Aroot Co. Ltd
KQ:096690
|
-0.026x |
|
Bridgemarq Real Estate Services Inc
TO:BRE
|
-0.044x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
AptaBio Therapeutics Inc
KQ:293780
|
-0.061x |
|
Many Peaks Minerals Ltd
AU:MPK
|
-0.020x |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
0.025x |
Annual Cash Flow Conversion Efficiency for OncoCyte Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of OncoCyte Corp from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see OncoCyte Corp (OCX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +285.17% |
| 2023-12-31 | $25.59 Million | $-23.32 Million | -0.911x | +31.42% |
| 2022-12-31 | $34.29 Million | $-45.57 Million | -1.329x | -141.12% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more